Synergy Pharma (SGYP) – StreetInsider.com Reports
-
Bausch Health Co. Inc. (BHC) Acquires Certain Assets of Synergy Pharmaceuticals Inc. (SGYP) for Approx. $195M in Cash
-
Synergy Pharma (SGYP) says Court entered an order approving implementation of Debtor's Key Employee Incentive Plan
-
Pre-Open Movers 12/12: (FOMX) (BTAI) (CORT) Higher; (SGYP) (NBIX) (PLAY) Lower (more...)
-
Bausch Health (BHC) Confirms 'Stalking Horse' Agreement to Acquire Substantially All Assets of Synergy Pharmaceuticals (SGYP)
-
Synergy Pharma (SGYP) Files Chapter 11, to Sell Most Assets to Bausch Health (BHC) for $200M
-
UPDATE: Synergy Pharma (SGYP) Reports In-Line Q3 EPS, Revenues Miss; Lowers FY18 Revenues Below Consensus & Below Min. Revenue Covenant on Loan Agreement
-
Synergy Pharma (SGYP) Names Dr. Melvin K. Spigelman as Chairman
-
Pre-Open Movers 10/26: (MLNX) (LOGM) (EXPE) Higher; (SGYP) (AMZN) (GOOGL) Lower (more...)
-
BTIG Downgrades Synergy Pharmaceuticals (SGYP) to Neutral
-
Canaccord Genuity Downgrades Synergy Pharmaceuticals (SGYP) to Hold
-
After-Hours Stock Movers 10/25: (MAT) (EXPE) (CMG) Higher; (SGYP) (AMZN) (GOOGL) Lower (more...)
-
Synergy Pharma (SGYP) Provides Update on Review, Said Offers 'Significantly Below' Current Market Value
-
Synergy Pharma (SGYP) Highlights New Analyses Supporting Use of TRULANCE (plecanatide) in Two Patient Populations
-
Synergy Pharma (SGYP) Strengthens Coverage for TRULANCE
-
Synergy Pharma (SGYP) Announces TRULANCE Added to Express Scripts 2019 National Preferred Formulary List
-
Synergy Pharma (SGYP) Enters License Agreement with Luoxin for TRULANCE in China
-
UPDATE: Ladenburg Thalmann Starts Synergy Pharmaceuticals (SGYP) at Buy
-
Synergy Pharma (SGYP) Reports Amendment to CRG Debt Agreement
-
Synergy Pharma (SGYP) to Present New Analysis of Therapeutic Risk and Benefit of TRULANCE and Linaclotide in CIC Patients at DDW
-
Paulson's 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more...)
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $6 at Cantor Fitzgerald
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $1.20 at Citi
-
Synergy Pharma (SGYP) Tops Q1 EPS by 1c, Sales Miss; Guides Lower
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $8 at Cantor Fitzgerald, Keeps 'Overweight'
-
Synergy Pharma (SGYP): Results Show Trulance Accelerating - HC Wainwright
-
Pre-Open Movers 01/03: (DRRX) (VSAR) (GPS) Higher; (OPK) (AOBC) (MCD) Lower (more...)
-
After-Hours Stock Movers 03/01: (DRRX) (VSAR) (GPS) Higher; (OPK) (AOBC) (OMER) Lower (more...)
-
Synergy Pharma (SGYP) Tops Q4 EPS by 3c, Beats on Revenues
-
Pre-Open Movers 02/28: (PHH) (AAXN) (ETSY) Higher; (FTR) (TSRO) (CELG) Lower (more...)
-
Cipher Acquires Canadian Rights to TRULANCE from Synergy (SGYP) for $5M Upfront
-
Pre-Open Movers 02/01: (OPGN) (AFMD) (ICPT) Higher; (EGOV) (ONCS) (UPS) Lower (more...)
-
Synergy Pharma (SGYP) Say it Achieved Cash Balance Requirement to Access Additional Capital
-
Synergy Pharma (SGYP): Approval Timing Indicates Greater Market Opportunity for IBS-C Than Discounted - HCWainwright
-
Pre-Open Movers 01/25: (DLB) (VAR) (MKC) Higher; (CFMS) (OCUL) (NWL) Lower (more...)
-
Synergy Pharma (SGYP) TRULANCE Approvd by FDA for IBS-C in Adults
-
UPDATE: Oppenheimer Downgrades Synergy Pharmaceuticals (SGYP) to Perform; 'Nagging Capital Overhang'
-
Synergy Pharma (SGYP) Names Troy Hamilton CEO
-
Synergy Pharma (SGYP): Cutting PT Ahead Of A Major Catalyst - HC Wainwright
-
Cantor Fitzgerald Maintains Bullish View on Synergy Pharmaceuticals (SGYP) Into Jan 24 PDUFA
-
Paulson's 13F Shows New Stake in Calpine (CPN), EQT (EQT), Sprint (S), Reduced Teva (TEVA), Exits Facebook (FB), AIG (AIG) (More...)
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $7 at BTIG; 'Factoring Risk of Additional Equity Financings by Late CY18 / Early CY19
-
Synergy Pharma (SGYP) Prices Common Stock and Warrant Offering
-
Synergy Pharma (SGYP) Tops Q2 EPS by 6c, Beats on Revenues
-
Synergy Pharma (SGYP) Presents Results from Study Examining Patient and Physician Perceptions and Experiences with IBS-C
-
Synergy Pharma (SGYP) to Highlight New Data for TRULANCE at WCOG
-
Synergy Pharma (SGYP) Sees Additional Gains; Shares 11%
-
Synergy Pharma (SGYP) Gains on Trulance Rx Data
-
Top 5 Performing Biotech Shorts in 2017 - S3 Partners
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $8 at H.C. Wainwright
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $2.50 at Citi
Back to SGYP Stock Lookup